News|Articles|May 4, 2026

AACE 2026 Recap: 5 Key Presentations to Know

Catch up on any data and perspectives presented at the American Association of Clinical Endocrinology Annual Meeting 2026.

The American Association of Clinical Endocrinology (AACE) Annual Meeting 2026, in Las Vegas, Nevada, brought together a number of key clinicians to share updates and advancements in everything from obesity and diabetes to thyroid health and growth hormone deficiencies. Trials like CAHtalyst Adult and discussions on topics like GLP-1s in type 1 diabetes (T1D) took center stage over the 3-day meeting.

Related to this article

October 27th, 2026

Diabetes Dialogue: Building A Consensus Definition for Fully Closed-Loop Systems

Brynn Marks, MD, MSHPEd, joins Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss a new framework defining fully closed loop insulin delivery.

October 23rd, 2026

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.

October 28th, 2026

TRANSCEND-T2D-2: Retatrutide Beats Semaglutide 2 mg on A1C, Weight Loss

Retatrutide lowered A1C 2.2% vs 1.8% and cut weight 19.5%-20.9% vs 9.4% with semaglutide 2 mg at 80 weeks in adults with type 2 diabetes.

November 2nd, 2026

What Phase 2 and 3 Data Show for Topical Difamilast in Atopic Dermatitis

Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.

November 2nd, 2026

Risankizumab Shows Higher 3-Year Drug Survival in Psoriasis With PsA

Final VALUE data show fewer drug changes with risankizumab vs other biologics over 37 months in patients with psoriasis and comorbid psoriatic arthritis.